Single-cell profiling of NSCLC tumor treated with Durvalumab and in combination with Tremelimumab.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.12104
Abstract: 12104Background: Combination of anti-PD1/L1 and anti-CTLA4 is under investigation for treatment of multiple tumors. However, how this combination modifies the immune micro-environment of tumors is ... read more here.
Keywords: single cell; combination; nsclc tumor; profiling nsclc ... See more keywords